This study aims to evaluate the clinical efficacy and safety of a multi-functional bilayering skincare regimen-consisting of a serum and cream-for improving skin brightness and reducing wrinkles. The formulation combines four active ingredients: Gamma-Aminobutyric Acid (GABA) 3%, Dimethylaminoethanol (DMAE) 2%, Cysteamine 2.5%, and Bakuchiol 1%. In an 8-week, double-blind, randomized, placebo-controlled trial involving 44 female subjects with Fitzpatrick skin types III-V, investigators will assess changes in skin brightness (L-value), wrinkle scores, pore counts, and melanin/erythema indices using standardized imaging and measurement tools. The primary goal is to determine if this specific combination therapy significantly enhances skin whitening and anti-aging outcomes compared to a placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
44
Gamma-Aminobutyric Acid (GABA) 3%
Formulations with identical sensory properties (color, scent, and texture) as the active products but lacking the four active ingredients.
Dimethylaminoethanol 2%
Cysteamine 2,5%
Bakuchiol 1%
Faculty of Medicine, Hasanuddin University
Makassar, South Sulawesi, Indonesia
Change in Skin Luminance (L*) as measured by Chromameter.
Skin color is assessed using the CIE Lab\* system. The L\* parameter specifically measures luminance/brightness on a scale of 0 (black) to 100 (white). An increase in L\* value indicates an improvement in skin lightness
Time frame: Baseline (Day 0) and Week 8 (Day 56).
Percentage change in skin wrinkles as assessed by Skin Analyzer.
The Skin Analyzer evaluates the depth and area of facial wrinkles through digital imaging, providing a percentage value of the analyzed area. A lower percentage indicates a reduction in wrinkle appearance.
Time frame: (Day 0) and Week 8 (Day 56).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.